Answers are grounded in this paper and cite their sources.
The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo.
No takes yet. Share an insight, caveat, or question.
Pieren et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: